View Older Stories View More Recent Stories
-
Eli Lilly (LLY) PT Raised to $1,350 at Cantor Fitzgerald as Strong Q2 Results Likely
-
Abbvie (ABBV) PT Raised to $265 at Cantor Fitzgerald: Broadly Strong Q2 Results Expected
-
RBC Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Innovent and Lilly strike China deal for breast cancer drug
-
FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing
-
FDA selects 7 companies for domestic drug manufacturing pilot
-
Sandoz submits generic obesity drug applications to FDA
-
Eli Lilly plans European weight-loss pill launch by early 2027
-
Sangamo files Chapter 11, agrees to sell assets to Lilly, Astellas
-
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.6% Yield
-
This digital health stock is ready to re-rate higher: Goldman
-
Eli Lilly (LLY) Reiterated at Overweight by Cantor Fitzgerald as Injectable Obesity TRx Down
-
Oral Wegovy reaches 33% of total prescriptions by May
-
Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)
-
BMO Capital on Eli Lilly (LLY): 'Early Data for AJ1-11095 Impress at EHA'
-
Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
-
Leerink highlights drug demand rebound after Memorial Day
-
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
-
Lilly's oral diabetes drug outperforms rival in late-stage trials
-
Bernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)
-
Truist on Eli Lilly (LLY): 'We see near-term and longer-term areas for growth'
-
Lilly reports weight loss data for Foundayo across menopause stages
-
Eli Lilly reports positive results for obesity drug retatrutide trials
-
Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
-
TD Cowen raises global GLP-1 sales forecast to $150B by 2030
-
ADA 2026 preview: All eyes on these 2 stocks
-
Weight Watchers integrates with Eli Lilly's LillyDirect platform
-
Lilly cuts Germany investment plan in half over healthcare reforms
-
Lilly to present hematology data at European meeting in Stockholm
-
Camurus (CAMX) announces expansion of Lilly collaboration, decision extends Lilly's exclusive, global rights to Camurus' FluidCrystal technology
-
Lilly's Retevmo reduces cancer recurrence risk by 83% in trial
-
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide
-
CVS Adds Lilly's Zepbound To Preferred Drug List In Reversal
-
Lilly acquires three infectious disease companies for up to $3.83 billion
-
Eli Lilly & Co. (LLY) to buy three vaccine firms for up to $4B - WSJ
-
Lilly's VERVE-102 reduces cholesterol by up to 62% in phase 1b trial
-
Eli Lilly (LLY) PT Raised to $1,251 at BofA Securities
-
Leerink Reiterates Outperform Rating on Eli Lilly (LLY)
-
China holds roundtable with over 50 foreign pharmaceutical firms
-
China Commerce Ministry holding meeting with foreign pharma companies including Lilly, Sanofi, Novartis, Merck
-
Eli Lilly reports weight loss data for obesity drug in older adults
-
Lilly to present oncology data at ASCO 2026 meeting
-
Eli Lilly & Co. (LLY) Acquires Engage Biologics for Up to $202M in Cash
-
Trump to unveil more discounted prescription drug options - CNBC
-
Eli Lilly loses Supreme Court appeal of $194 million fraud award
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Eli Lilly launches Alzheimer's drug in India at $957 per vial
-
Lilly reports weight maintenance with Foundayo and reduced-dose Zepbound
-
FDA Commissioner Marty Makary to step down - Politico
-
Health officials explore restrictions on certain SSRI antidepressants - Reuters
